Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs in Recurrent/Refractory NSCLC
NCT04919616Phase 1Unknown
- Sponsor
- OriCell Therapeutics
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in non-small cell lung cancer (NSCLC), sponsored by OriCell Therapeutics. Primary endpoint: Dose limiting toxicity at 28 days. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04919616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919616.